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INTRODUCTION
of the gastric body, whereas antral biopsies were obtained from the lesser curvature. Th e unexpected results of these studies led us to question whether the concept that most stomachs could be characterized as either normal or H. pylori -infected (active or past infection) might be too simple. However, those two studies were relatively limited by their biopsy protocols, the reliance of histology alone (i.e., the lack of adjustment for previous H. pylori treatment or potential confounders such as smoking, alcohol, nonsteroidal anti-infl ammatory drug (NSAID), or proton pump inhibitor (PPI) use) ( 5 ) . To investigate the prevalence and risk factors associated with H. pylori-negative gastritis, we performed gastric mapping to identify gastritis in a large number of patients undergoing endoscopy. We also used histology, culture, serology, and past treatment history to identify H. pylori .
METHODS

Study population and design
We performed a cross-sectional study at the Michael E. DeBakey Veterans Aff airs Medical Center in Houston, TX. Between 15 February 2008 and 18 February 2009, we invited all consecutive eligible patients who were scheduled for an elective esophagastroduodenoscopy (EGD) to participate. We also invited a group of randomly selected eligible patients who were scheduled for a primary care clinic visit at the same hospital to undergo an EGD at the same time as their screening colonoscopy.
Recruitment and eligibility criteria
Th e electronic medical records of all veterans with a scheduled EGD were screened to determine study eligibility, based on the following criteria: (i) age between 40 and 80 years; (ii) no previous esophageal surgery or surgical resection of the esophagus or stomach; (iii) no previous cancer of the esophagus; (iv) no active lung, liver, colon, breast, or stomach cancer; (v) no current use of anticoagulants; (vi) no signifi cant liver disease, indicated by platelet count below 70,000, ascites, or known gastroesophageal varices; and (vii) no history of major stroke or mental condition that would limit ability to answer questions.
Esophagastroduodenoscopy
All study participants underwent an EGD with systematic recording of specifi c fi ndings. Gastric mapping was performed by taking seven mucosal biopsy samples from the antrum, corpus, incisura angularis, lesser curvature, greater curvature, and cardia with biopsies separately identifi ed ( Figure 1 ). Th is protocol follows the recommendations of the International Workshop on Histopathology of Gastritis ( 6 ) . We recorded the presence of gastric erosions. Live-case orientation sessions were conducted with the endoscopists involved in the study to demonstrate landmarks and biopsy sites.
Histopathological examination
All biopsy specimens were embedded in paraffi n, oriented on edge, sectioned in 5-μ sections, and stained with: (i) a triple stain consisting of hematoxylin and eosin, alcian blue at pH 2.5; and in case of negative staining for H. pylori (ii) a modifi ed silver stain; and (iii) alcian blue-Periodic acid Schiff stain. Biopsies were ( 6 ) . Equivocal cases were also examined using immunostaining for H. pylori . In addition, the study pathologist systematically recorded PPI eff ect defi ned as jagged protrusion of hyperplasic oxyntic cells into dilated glandular lumens.
Serology
Serum samples from all study subjects were evaluated for IgG antibody to the high-molecular-weight, cell-associated proteins of H. pylori , using an enzyme-linked immunosorbent assay ELISA (HM-CAP, EPI, Westbury, NY). Th e test was scored positive when the optical density was > 2. Th is test has a reported sensitivity of > 97 % and a specifi city of > 94 % for adults ( 7 ) .
Cultures
Biopsy specimens from all study subjects were placed in sterile vials containing cysteine medium with 20 % glycerol and stored at − 80 ° C until cultured. Th e frozen specimens were then thawed and the tissue was homogenized and inoculated onto two types of selective media; Brain Heart Infusion and H. pylori Special Peptone Agar plates with 7 % horse blood. Th e plates were incubated at 37 ° C under microaerophilic conditions. Th e negative plates were reincubated and then read every 24 h up to 14 days. Positive growth was transferred to a fresh, nonselective Brain Heart Infusion blood agar plate and then incubated for 48 -72 h. H. pylori was identifi ed defi nitively when the oxidase, catalase, and urease reactions were positive with a compatible Gram-negative stain.
Survey questionnaire
All study participants completed a computer-assisted survey before the EGD that included questions on demographic features, use of several medications, previous treatment for H. pylori , tobaccosmoking status, and alcohol drinking. For this analysis, past and current PPI use was based on self-reported use of any of the following medications: omeprazole, lansoprazole, pantoprazole, rabeprazole, or esomeprazole. Histamine-2 receptor antagonist use was based on self-reported use of any of the following medications: cimetidine, ranitidine, nizatidine, or famotidine. Aspirin or NSAID use was defi ned based on self-reported current use of any of 31 named medications. Given some features of gastritis persist for some time aft er eradicating H. pylori , previous H. pylori treatment was ascertained to avoid misclassifying H. pylori -negative gastritis Alcohol drinking was defi ned based on answers to 28 questions about current and past drinking and was operationalized as the patient ' s being a nondrinker, current drinker, or past drinker if the patient had quit drinking >1 year earlier.
Smoking status was defi ned as being a current smoker by smoking at least 100 cigarettes, cigars, or pipes in a lifetime and being a current smoker on the date of the interview; being a nonsmoker, with a lifetime history of smoking < 100 cigarettes, cigars or pipes; or being a past smoker, who had quit smoking >1 year ago.
For cases negative for H. pylori (staining, culture, serology), the slides were re-examined for features of sarcoidosis, eosinophilic gastritis, lymphocytic gastritis, and autoimmune gastritis. We also examined the medical records and self-reported history of infl ammatory bowel disease.
Analysis
We defi ned gastritis by the presence of at least grade 2 neutrophils or mononuclear cells in at least one gastric biopsy site, or grade 1 neutrophils or mononuclear cells in at least two sites ( Table 1 ; 8, 9 ) . In a sensitivity analysis, gastritis was defi ned as at least grade 2 neutrophils or mononuclear cells in at least two biopsy sites. To be considered H. pylori -negative, an individual had to fulfi ll all four of the following criteria: (i) a negative triple staining of gastric mucosa in all seven sites (hematoxylin and eosin, alcian blue at pH 2.5, and a modifi ed silver stain); (ii) a negative H. pylori culture; (iii) a negative IgG H. pylori serology (HM-CAP ELISA); and (iv) no self-reported previous H. pylori treatment ( Figure 2 ) .
We compared the demographic and clinical features for patients with and without gastritis, and among those with gastritis we compared those with and without H. pylori infection. For the latter group, we also examined the proportions with antrum or corpus atrophy or intestinal metaplasia as well as overall atrophy (OLGA staging). χ 2 tests were used for categorical variables and t -tests for continuous variables. We also conducted an adjusted analysis using multivariable logistic regression to examine the possible predictors of H. pylori-negative gastritis. To avoid overfi tting the model, we adjusted each predictor of interest for age and race only. SAS (version 9.2, SAS Institute, Cary, NC, USA) was used to conduct the analyses. 
RESULTS
Th e participation rates among patients who appeared in person to their endoscopy or clinic appointments were 78 and 50 % , respectively. In the 12-month period described in the Methods, we included the fi rst 491 participants who gave informed consent, completed the survey, and underwent endoscopy in this study ( Figure 2 ) ; 458 (93.3 % ) were from those referred to endoscopy and 33 (7.7 % ) from patients recruited from primary care for colonoscopy and EGD. Th ere were no signifi cant diff erences in age, sex, or race distribution based on the source of enrollment. Positive on at least one of triple staining, culture, or serology. c P < 0.0001 between gastritis and nongastritis, and 0.08 between H. pylori -negative and -positive gastritis. 
STOMACH
Helicobacter pylori -negative gastritis antrum only in 15 (37 % ), in the corpus only in 13 (32 % ) and in both the antrum and corpus in 13 (32 % ), with none in the cardia alone (data not shown). Th is was diff erent from subjects with H. pylori-positive acute or chronic gastritis, 70 % of whom had both antrum and corpus distribution ( n = 111). Th ere were also no signifi cant diff erences in the proportions of patients with atrophy or intestinal metaplasia between patients with H. pylori -negative or -positive gastritis ( Table 3 ). Although 17, 41.5 % of patients with H. pylori -negative gastritis had atrophy recorded in antral or body biopsies, the overall atrophy as indicated by OLGA score was mild in most cases (15 of 19 had grade 1 or 2).
Patients with H. pylori -negative gastritis were more likely to have a history of past alcohol drinking and smoking rather than current drinking or smoking than patients with H. pylori -positive gastritis ( Table 4 ) . Both past and current PPI use was more commonly reported in the H. pylori-negative gastritis group, but these diff erences did not reach statistical signifi cance ( Table 4 ). Histological changes in the gastric mucosa suggestive of PPI use were recorded in 53.7 and 54.1 % of H. pylori -negative and -positive gastritis, respectively. In addition, there were no signifi cant diff erences in the proportions of subjects with self-reported histamine 2 receptor antagonists or aspirin / NSAID between the two gastritis groups.
Th e medical records of the 41 individuals with H. pylori-negative gastritis were manually reviewed in detail by one investigator (D.Y.G.) to check for previous H. pylori diagnosis or treatment. Only one subject was found to have had previous H. pylori treatment that was not captured by the survey. One patient had lymphocytic gastritis, and another one had autoimmune gastritis.
In the age-and race-adjusted analyses conducted among the 200 patients with any gastritis, none of the lifestyle factors (alcohol or smoking) or medication use (PPI, histamine 2 receptor antagonists, or NSAID) were signifi cantly associated with H. pylori -n egative gastritis ( Table 5 ) . Th e risk estimates derived from the model were, however, in the same direction as those reported in the unadjusted analyses ( Table 4 ).
Of these study subjects, 200 (40.7 % ) were found to have histological gastritis, defi ned as at least grade 1 in at least two gastric sites ( n = 189) or at least grade 2 in at least one gastric site ( n = 11). Th e group of 159 subjects with H. pylori -positive gastritis were identifi ed based on positive culture ( n = 52), positive triple staining (44 defi nite and 34 possible), positive serology ( n = 22), and previous self-reported H. pylori treatment ( n = 7). Th e remaining 41 individuals (20.5 % of all subjects with gastritis and 8.4 % of the total study population) had gastritis on histological examination but were negative for active or past H. pylori infection.
In general, subjects with any gastritis were more likely to be older, male, and Black; but only the higher proportion of Blacks was statistically signifi cant compared with those without gastritis ( Table 2 ) . Subjects with H. pylori-positive gastritis were also slightly more likely to be Black ( P = 0.08) than subjects with H. pylori-negative gastritis.
Most of the gastritis in the H. pylori -negative group was chronic, whereas both acute and chronic were present in most cases in the H. pylori -positive group ( Table 3 ). In the H. pylori -negative group, gastritis was also more likely to be present in isolated portions of the stomach than in the H. pylori -positive group. In the non-H. pylori group, acute or chronic gastritis was present in the Lastly, the defi nition of gastritis used was robust in the sensitivity analysis. Th e number of subjects with gastritis changed very little with a defi nition of at least grade 2 neutrophils or mononuclear cells in at least two biopsy sites ( n = 192, all of whom were part of the 200 considered in the main analyses).
DISCUSSION
In this population, we found that H. pylori -negative gastritis, as confi rmed by three diff erent diagnostic methods and without previous H. pylori treatment, was relatively infrequent (8.4 % ). However, H. pylori -negative gastritis was found in about 21 % of our patients with gastritis on histopathologic examination. Although diff erences were not statistically signifi cant, patients with H. pylori -negative gastritis were more likely to use PPIs and to be past alcohol drinkers and tobacco smokers (rather than current ones) compared with patients with H. pylori -positive gastritis.
Previous studies on the prevalence of gastritis in H. pylorinegative individuals have shown that as many as 75 -90 % had evidence of gastritis ( 3, 4 ) . However, the patient population in these studies was part of clinical trials of PPIs for upper gastrointestinal diagnoses (erosive esophagitis, nonerosive refl ux, and functional dyspepsia). Th e demographic composition was 33 % women and 90 % white (as compared with 7 % women and 70 % white in our study). Although the authors of one of these study report that the H. pylori -negative status remain unchanged in almost 7 years of follow-up 3 , some patients who were characterized as H. pylorinegative in these studies might actually have been positive. First, only four biopsies were taken (two from the antrum and two from the corpus), whereas the new Sydney System requires at least fi ve specimens, as well as a visual analog scale to compare and score the fi nding. Second, histopathologic review was done by only one pathologist. Finally, H. pylori diagnosis was made only on the basis of Warthin-Starry silver staining, potentially misclassifying H. pylori-positive individuals as H. pylori negative; and past history of H. pylori treatment was not accounted for. Th ese biases were likely to underestimate H. pylori infection. Our defi nition of H. pylori negative was meant to be stringent and highly specifi c by using multiple methods of ascertainment. We acknowledge that in routine clinical practice where one method of diagnosis is usually used, the prevalence of H. pylori -negative gastritis would be higher.
Reasons for H. pylori -negative gastritis in our study are unknown but may include the following:
Previous H. pylori infection that was treated but not recollected by study participants or not captured by the VA medical records due to therapy being obtained at a non-VA facility. However, IgG serology used in this study has been shown to remain positive a long time aft er H. pylori eradication. In one study, 3.5 years aft er successful H. pylori treatment, 72 % remained seropositive according to ELISA, and 62 % remained positive according to rapid serum immunoassay ( 10 ) . Th erefore, previous infection was likely to have been detected on ELISA. PPI use . In the study population, 68 % of those with H. pylori-negative gastritis either were previous or current • • users of PPI, and 54 % had histologic features of PPI use. Animal studies have suggested that long-term PPI use can lead to gastric inflammation, possibly through microbial overgrowth ( 11 ) . Furthermore, in previous studies of H. pylori -negative gastritis, long-term lansoprazole treatment was associated with reductions in acute and chronic inflammation of the gastric body and antrum ( 3 ). It is also possible that PPI is a marker of GERD (gastroesophageal reflux disease), which is less likely to be present in Hpnegative subjects. This may also explain why Hp-gastritis was more common in the prior referenced studies that were enriched with GERD subjects. Autoimmune gastritis , associated with serum antiparietal and anti-intrinsic factor antibodies and the cause of pernicious anemia, is characterized by a chronic atrophic gastritis limited to the mucosa of the corpus and fundus and by a marked diffuse atrophy of parietal and chief cells. While gastric atrophy was present in 36.6 % of subjects with H. pylori -negative gastritis, the gastritis was limited to the corpus in only one-third of these subjects. Further detailed examination confi rmed only one case of autoimmune gastritis. We did not measure antiparietal antibodies in these patients. Infection by organisms other than H. pylori (e.g., Mycobacterium avium-intracellulare, Herpes simplex , and Cytomegalovirus are a few examples of organisms that can invade the gastric mucosa and cause infl ammation). However, these infections are extremely rare in patients who are not immunocompromised. We have not specifi cally evaluated for other infective causes of gastritis. Chemical or reactive gastritis , oft en caused by bile refl ux or NSAID use. Almost half of the 41 subjects with H. pylorinegative gastritis were either past or current NSAID users. However, NSAID intake usually causes lesions with only minimal infl ammation and should be easily distinguishable on histopathology. Causes such as collagenous gastritis, Crohn ' s disease-associated gastritis, sarcoidosis, eosinophilic gastritis, lymphocytic gastritis are all rare and relatively easy to distinguish on histopathologic examination.
Th e clinical relevance and prognosis of H. pylori -negative gastritis is unknown and need to be further examined given the relatively high prevalence of this entity. For example, it is unclear if the risk of ulcer of cancer is increased, or if it predisposes to upper gastrointestinal symptoms. However, it is at least clear that in clinical practice, empirical treatment for H. pylori is not warranted in patients with gastritis without clear evidence for the presence of this infection.
Th is study has some limitations, including the characteristics of the study base population, mostly men with low socioeconomic status and high prevalence of H. pylori infection, PPI use and NSAID use, which could decrease the external validity of the study to nonveteran men or women. Th e small sample size may have resulted in lack of power to detect the diff erences in possible risk factors between H. pylori -positive and -negative groups.
• • • • However, the internal validity is strengthened by the use of three diff erent methods to diagnose H. pylori infection and the additional medical record review to confi rm H. pylori-negative status, thus reducing the risk of misclassifi cation of H. pylori status. Using self-reported past H. pylori treatment to defi ne H. pylori as a cause of the gastritis may have misclassifi ed few cases with H. pylori-negative gastritis that arose subsequent to H. pylori eradication. Furthermore, strict histopathological criteria were used for diagnosis; and all cases were reviewed by two gastrointestinal pathologists.
In conclusion, H. pylori -negative gastritis was present in ~ 21 % of gastritides. Very few cases had an alternative known cause (autoimmune in only one person). Non-H. pylori gastritis was typically mild and more focal than H. pylori gastritis and tended to be chronic rather than chronic-active or active. PPI use is a potential risk factor for H. pylori-negative gastritis, but the causes and implications of this entity are unknown and are worthy of future studies.
